| Total: $230.14M | ||||
| Company (Symbol)# (M) |
Type Of Financing |
Number Of Shares, Units Or Warrants |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
|
Adherex Technologies Inc. (AMEX:ADH) |
Private placement of units | 30.3U | $10 | Versant Partners Inc. agreed to purchase 30.3M units priced at 33 cents each; it also may buy an additional 45.5M units at the same price for additional proceeds of $15M; each unit consists of one common share and one-half of a common share purchase warrant (1/22) |
|
Advanced Viral Research Corp. (OTC BB: ADVR) |
Private placement of convertible notes and warrants | N/A and 48.1W | $1.5 | The three-year, 9% notes were purchased by Cornell Capital Partners; the notes are convertible into stock at the lesser of $0.0312 per share, or 95% of the lowest 30-day price; the five- year warrants are exercisable at $.0312 per share (1/8) |
|
Avalon Pharmaceuticals Inc. (AVRX) |
Private placement of common stock | 3S | $10 | Company agreed to sell to institutional investors 3M shares at $3.34 each; investors were Federated Kaufman Funds, Merlin Nexus II LP, Passport Management LLC, Xmark Opportunity Funds and Biotechnology Value Fund (1/23) |
|
Bionovo Inc. (OTC BB:BNVI) |
Private placement | N/A | $15.7 | RA Capital participated in the round, along with Paramount BioCapital Asset Management, Ironwood Capital and a group of new and existing private shareholders (1/22) |
|
Cortex Pharmaceuticals Inc. (AMEX:COR) |
Private placement of common stock and warrants | 5S and W for 3.3S | $5.6 | Several institutional investors agreed to purchase the stock; the warrants can be exercised for $1.66 per share; Roth Capital Partners acted as exclusive placement agent (1/17) |
|
ExonHit Therapeutics SA (France; Euronext:ALEHT) |
Exercise of warrants | W for 0.410S | $4.1 | ExonHit received $4.1M through the exercise of warrants leading to the issuance of 409,815 new shares (1/25) |
|
FermaVir Pharmaceuticals Inc. (OTC BB:FMVR) |
Private placement of shares and warrants | 1.693S and W for 3.387S | $1.27 | FermaVir raised $1.27M selling its shares and 10- year warrants (1/16) |
|
Genelabs Technologies Inc. (GNLB) |
Equity sale | 7.1S | $2.2 | Genelabs sold 7.1M shares, its remaining equity, in Genovate Biotechnology Co. Ltd., of Taiwan (1/29) |
|
GPC Biotech AG (Germany; GPCB) |
Private placement of stock | 1.6S | |33.6 (US$43.7) | GPC priced the shares at |21.50 each (1/24) |
|
Icagen Inc. (ICGN) |
Private placement of common stock and warrants | 15.4S and W for 5.4S | $22 | Investors included Greenway Capital, QVT, Venrock Associates, Alta Partners and an affiliate of Quintiles Transnational Corp. (1/29) |
|
Inflazyme Pharmaceutical Ltd. (Canada; TSX:IZP) |
Private placement of units | 17.6U | C$3 (US$2.54) | Inflazyme agreed to issue 17.6M units at 17 cents per unit (1/24) |
|
International Stem Cell Corp. (OTC BB:ISCO) |
Private placement of capital stock | ND | $11.2 | International Stem Cell raised $11.2M prior to its share exchange transaction with BTHC III Inc. (1/8) |
|
Matritech Inc. (AMEX:MZT) |
Private placement of secured convertible promissory notes | Notes and W for 4.16S | $4.36 | Matritech closed a $4.36M private placement of Series B 15% secured convertible promissory notes and five-year warrants to purchase about 4.16M shares; investors were SDS Capital Group SPC Ltd., H&Q Life Science Investors and various ProMed funds (1/23) |
|
MicroIslet Inc. (AMEX:MII) |
Private loan | W for 0.5S | $2 | Chairman John Hagenbuch is providing a $2M cash l oan in exchange for a 10-year warrant allow- him to purchase up to 500,000 shares at $1 each (1/16) |
|
Monogram Biosciences Inc. (MGRM) |
Private placement of convertible senior unsecured notes | N/A | $30 | The 0% convertible senior unsecured notes due 2026 were sold to a single institutional buyer (1/12) |
|
Napo Pharmaceuticals Inc. (LSE:NAPL) |
Private placement of stock | 3.514S | £3.15 ($6.2) | The shares were placed at 94.5 pence each, the Jan. 5 closing price (1/8) |
|
Targeted Genetics Corp. (TGEN) |
Private placement of stock and warrants | 2.18S and 0.763W | $8.72 | The stock was sold at $4 per share, a 16% discount to the 45-day average; the warrants are exercisable at $5.41per share; the lead investor was Special Situations Fund; Greenway Capital also invested; Pacific Growth Equities LLC was placement agent (1/8) |
|
Resverlogix Corp. (Canada; TSX:RVX) |
Private placement of convertible notes and warrants | N/A and 0.41W | $17 | The three-year, 8% notes are convertible into stock at C$12.07 per share; the warrants are exercisable C$15.09 per share; Oppenheimer & Co. Inc. was placement agent; Caris 7 Co. was co-agent (1/2) |
|
SkyePharma plc (UK; SKYE) |
Private placement of stock | 61.2S | £14.8 ($29) | SkyePharma is placing up to 61.2M shares at 24.5 pence per share (1/9) |
|
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) |
Private placement of units | N/A | C$2 (US$1.7) | Each C20-cent unit is comprised of one common share and one half of one common share purchase warrant exercisable for 24 months at C25 cents (1/22) |
|
Wex Pharmaceuticals Inc. (Canada; TSX:WXI) |
Private placement of stock | 8.75S | C$1.575 ($1.35) | Investors purchased the shares at C$0.18 each (1/9) |
| Notes: | ||||
| This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| N/A = Not applicable; ND = Not disclosed. | ||||
| AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
